There are currently 428 active clinical trials seeking participants for Breast Cancer research studies. The states with the highest number of trials for Breast Cancer participants are California, Ohio, Illinois and Michigan.
SABER Study for Selected Early Stage Breast Cancer
NCT04360330
Recruiting
The purpose of this study is to find the most effective dose of radiation therapy to give to breast tumors in a shorter period of time, prior to standard partial mastectomy/axillary surgery.
Gender:
FEMALE
Ages:
50 years and above
Trial Updated:
06/04/2025
Locations: University of Miami, Miami, Florida
Conditions: Breast Cancer, Early-stage Breast Cancer
Register for Updates
Opioid-Sparing Effects of Nurse-Delivered Hypnosis During Breast Cancer Surgery
NCT05766891
Recruiting
To hypnosedation alone given before and during surgery on reducing opioid use after surgery compared to standard general anesthesia given alone or with hypnosedation.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/04/2025
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Breast Cancer
Register for Updates
A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors
NCT06440005
Recruiting
AGX101 is an antibody-drug conjugate (ADC) therapy for tumor-forming cancers. The purpose of this study is to learn about AGX101 effects and safety at various dose levels in an all-comers advanced solid cancer patient population. AGX101will be administered intravenously. Dosing of AGX101 will be repeated once every 3, 6 or 9 weeks. Participants may continue study treatment until disease progression, unacceptable toxicity, or consent withdrawal. Subjects will attend an end of treatment visit and... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/04/2025
Locations: Sarah Cannon Research Center, Nashville, Tennessee +2 locations
Conditions: Cancer, Advanced Cancer, Locally Advanced Carcinoma, Metastatic Solid Tumor, Breast Cancer, Prostate Cancer, Colorectal Cancer, Pancreatic Cancer, Liver Cancer, Angiosarcoma, Solid Tumor
Register for Updates
Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of BTX-9341 in Advanced and/or Metastatic Breast Cancer
NCT06515470
Recruiting
The purpose of this study is to test BTX-9341 alone or in combination with fulvestrant (a currently marketed medication for breast cancer) in participants with advanced and/or metastatic hormone receptor positive (HR+)/human epidermal growth factor receptor 2 negative (HER2-) breast cancer. The study includes a dose escalation part (Part A) where small groups of participants will receive increasing doses of BTX-9341 or BTX-9341 + fulvestrant followed by a dose expansion part (Part B) where parti... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/04/2025
Locations: Biotheryx Investigative Site, Rochester, Minnesota +5 locations
Conditions: Breast Cancer
Register for Updates
Identifying Underserved Individuals inTexas With Hereditary Cancer Risk Using Mobile Mammography Units and Telegenetics.
NCT05649072
Recruiting
Identifying women at risk for hereditary cancer potentiates prevention, early detection or personalised treatment against cancer. We using mobile mammography units will provide genetic sceening and testing services to underserved women coming for thier mammograms to these units.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
06/03/2025
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Ovarian Cancer, Breast Cancer, Colorectal Cancer
Register for Updates
A Phase II Study of Neoadjuvant Sacituzumab Govitecan and Pembrolizumab Therapy for Immunochemotherapy-resistant Early-stage Triple-negative Breast Cancer (TNBC)
NCT05675579
Recruiting
To learn if sacituzumab govitecan and pembrolizumab, when given before surgery, can help to control early-stage triple negative breast cancer that has not responded well to other treatments.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/03/2025
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Breast Cancer
Register for Updates
Memantine and Exercise to Improve Cognitive Function and Modulate Biological Pathways of Cognitive Decline During Chemotherapy in Breast Cancer
NCT06727773
Recruiting
This randomized, placebo-controlled trial aims to assess the feasibility, acceptability, and preliminary efficacy of memantine and the University of Carolina (UNC)'s Get Real \& Heel cancer exercise program (MEM+EX) in addressing cancer-related cognitive impairment (CRCI) and underlying CRCI biomarkers. Ninety stage I-III breast cancer patients with mild cognitive difficulties during chemotherapy will be randomized into three groups: MEM+EX, memantine, or placebo. The study will evaluate recruit... Read More
Gender:
FEMALE
Ages:
50 years and above
Trial Updated:
06/03/2025
Locations: Lineberger Comprehensive Cancer Center at University of North Carolina, Chapel Hill, Chapel Hill, North Carolina
Conditions: Breast Cancer, Locally Advanced Breast Cancer, Cognitive Impairment, Cognitive Decline, Cognitive Change, Breast Cancer Stage I, Breast Cancer Stage II, Breast Cancer Stage III
Register for Updates
The C-MERIT Screening Cohort: Contrast-enhanced Mammography for Breast Cancer Screening and Risk Assessment in Women With Dense Breasts
NCT05667532
Recruiting
To learn whether a new imaging technology, Contrast-Enhanced Mammography (CEM), compared to standard mammography, can better detect breast cancers in women with dense breasts
Gender:
FEMALE
Ages:
Between 30 years and 75 years
Trial Updated:
06/02/2025
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Breast Cancer
Register for Updates
Study of Aerobic Training for People Receiving Chemotherapy for Breast Cancer
NCT05716893
Recruiting
In this study, investigators will compare standard Aerobic Training/AT with adaptive Aerobic Training/AT. Standard AT will be a fixed (unchanging) amount of walking each week, while adaptive AT will adjust the level of exercise depending on participants' response to the exercise. Investigators will see how both study approaches (standard AT and adaptive AT) affect participants' CRF.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
06/02/2025
Locations: Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey +6 locations
Conditions: Breast Cancer, Breast Carcinoma
Register for Updates
Fecal Microbiota Transplantation in Treating Immune-Checkpoint Inhibitor Induced-Diarrhea or Colitis in Genitourinary Cancer Patients
NCT04038619
Recruiting
This trial studies how well fecal microbiota transplantation works in treating diarrhea or colitis (inflammation of the intestines) that is caused by certain types of medications (called immune-checkpoint inhibitors) in patients with genitourinary cancer. Fecal microbiota transplantation may effectively reduce the incidence of immune checkpoint inhibitor-induced diarrhea/colitis.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/30/2025
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Colitis, Diarrhea, Malignant Genitourinary System Neoplasm, Melanoma, Lung Cancer, Ovarian Cancer, Uterine Cancer, Breast Cancer, Cervical Cancer
Register for Updates
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
NCT06293898
Recruiting
The objective of this study is to evaluate the safety, tolerability, and efficacy of BL-M07D1 in patients with HER2 expressing advanced tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/30/2025
Locations: City of Hope, Duarte, California +9 locations
Conditions: Endometrial Cancer, Cervical Cancer, Ovarian Cancer, Urothelial Carcinoma, Biliary Tract Cancer, Breast Cancer, Lung Cancer, Gastric Cancer, Gastroesophageal-junction Cancer, Esophageal Cancer
Register for Updates
Breast Elasticity Imaging During Neoadjuvant Chemotherapy
NCT04824027
Recruiting
For this study, the investigators propose investigation of a new imaging technique, Harmonic Motion Imaging (HMI), and the evaluation of its potential role in prediction of breast cancer response to neoadjuvant chemotherapy (NACT). The investigators hypothesize that changes in HMI parameters will predict response to neoadjuvant systemic therapy in early-stage breast cancer.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
05/28/2025
Locations: Columbia University Irving Medical Center/NYP, New York, New York
Conditions: Breast Cancer
Register for Updates